skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProNAI Therapeutics, armed with two in-licensed assets focused on DNA damage repair (DDR) and USD 100 million in the bank.
Sierra Oncology president and CEO Dr. Nick Glover explains how the company is rebranding itself from its former incarnation ProNAI Therapeutics.

 

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: